Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ITM-91
- Development stage
- Phase 2
- Lead developer
- ITM Isotope Technologies Munich
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Peptides
- Administration
- Intravenous
01
Overview
ITM-91 is a Lutetium-177-labeled radioligand therapeutic compound developed for the treatment of unresectable locally advanced or metastatic solid tumors, including clear cell renal cell carcinoma (ccRCC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC)[1][2][3][5][6]. It consists of chemically stabilized peptide ligands (peptidomimetics) that target the Carbonic Anhydrase IX (CA IX) surface protein—a key player in tumor growth and metastasis—conjugated to a therapeutic radioisotope via a linker[1][2]. The drug is administered intravenously as part of a theranostic pair with an imaging agent ([68Ga]Ga-DPI-4452/ITM-94D). Its mechanism involves selective binding to CA IX-expressing tumor cells and delivering targeted radiotherapy through Lutetium-177 decay. Originally developed by Debiopharm as Debio 0228, it is now licensed globally to ITM Isotope Technologies Munich SE for clinical development[1][5].
- Other names
- ITM-91ITM91ITM 91Debio 0228Debio0228Debio-0228[177Lu]Lu-DPI-4452
02
Targets
CA9 (Carbonic anhydrase IX)
Beyond the preview
Go deeper on ITM-91.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ITM-91.